NewsMarkets

Business

AstraZeneca Invests $2 Billion in Summit Therapeutics for Cancer Drug Development

The pharmaceutical giant will jointly develop drugs with the cancer drugmaker following a strategic equity investment.

2 publishers · 2 articles · first seen 28 Sept 2026 · updated 56m ago

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal Bloomberg Markets ·
  2. AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows South China Morning Post

In this story

  • Summit Therapeutics
  • AstraZeneca

Related stories